Business
Surrozen Provides First Quarter 2024 Financial Results and Business Update
SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO
About this update from Surrozen, Inc.
[{"type":"text","content":"SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based Wnt mimetic, to activate targeted cell regeneration in cornea endothelial dystrophies and dry eye disease SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates. “2024 is expected to be an important year focused on advancing the SZN-043 Phase 1b trial toward proof-of-concept data in patients with severe alcohol-associated hepatitis and communicating data from key R&D programs focused on Wnt modulation at upcoming medical meetings and in publications,” said Craig Parker, President and Chief Executive Officer of Surrozen. “Surrozen remains driven to transform the treatment of severe diseases of the liver and eye, where we believe Wnt modulation plays an essential role.” Research and Development Pipeline Highlights SZN-043Surrozen is developing SZN-043 for severe liver disease with an initial focus in severe alcohol-associated hepatitis. Clinical Development Timelines/Milestones: Completed Phase 1a study in healthy volunteers and chronic liver disease patients in the first quarter of 2024Regulatory filings submitted in multiple countries for Phase 1b study and enrollment is expected to begin in the second quarter of 2024Anticipate proof-of-concept data may be available in the first half of 2025 Research Pipeline Programs and Publications Surrozen presented preclinical data at 2024 ARVO that suggests that activation of the Wnt pathway through the company’s antibody based Wnt mimetic may provide a novel approach to treatment of severe eye diseases -- cornea endothelial dystrophies and dry eye diseaseSurrozen published study in Respiratory Research demonstrating the promise of a Wnt mimetic antibody in treating pulmonary fibrosis (April, 2024: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-024-02786-2) In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased pulmonary inflammation and fibrosis ...